Technical Analysis for PRAX - Praxis Precision Medicines, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 1.28% | |
| NR7-2 | Range Contraction | 1.28% | |
| Multiple of Ten Bullish | Other | 1.28% | |
| NR7 | Range Contraction | 3.03% | |
| Multiple of Ten Bullish | Other | 3.03% | |
| Down 3 Days in a Row | Weakness | 3.03% | |
| Down 4 Days in a Row | Weakness | 3.03% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| 20 DMA Resistance | about 20 hours ago |
| Rose Above 20 DMA | about 20 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| Up 2% | about 20 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/05/2024
Praxis Precision Medicines, Inc. Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Depression Central Nervous System Disorders Epilepsy Major Depressive Disorder Precision Medicine Nervous System Disorders Depressive Disorder Huntington's Disease Oligonucleotide Spinal Muscular Atrophy Treatment Of Major Depressive Disorder Neuron Antisense RNA Essential Tremor Receptor Positive Ionis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 86.93 |
| 52 Week Low | 14.8 |
| Average Volume | 306,373 |
| 200-Day Moving Average | 54.30 |
| 50-Day Moving Average | 67.84 |
| 20-Day Moving Average | 73.86 |
| 10-Day Moving Average | 76.93 |
| Average True Range | 5.17 |
| RSI (14) | 52.15 |
| ADX | 21.19 |
| +DI | 17.84 |
| -DI | 25.60 |
| Chandelier Exit (Long, 3 ATRs) | 71.43 |
| Chandelier Exit (Short, 3 ATRs) | 74.34 |
| Upper Bollinger Bands | 82.95 |
| Lower Bollinger Band | 64.76 |
| Percent B (%b) | 0.49 |
| BandWidth | 24.62 |
| MACD Line | 1.93 |
| MACD Signal Line | 2.76 |
| MACD Histogram | -0.8277 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 79.19 | ||||
| Resistance 3 (R3) | 78.91 | 76.79 | 78.27 | ||
| Resistance 2 (R2) | 76.79 | 75.39 | 76.93 | 77.96 | |
| Resistance 1 (R1) | 75.24 | 74.53 | 76.02 | 75.52 | 77.66 |
| Pivot Point | 73.12 | 73.12 | 73.51 | 73.26 | 73.12 |
| Support 1 (S1) | 71.57 | 71.72 | 72.35 | 71.85 | 69.70 |
| Support 2 (S2) | 69.45 | 70.86 | 69.59 | 69.40 | |
| Support 3 (S3) | 67.90 | 69.45 | 69.09 | ||
| Support 4 (S4) | 68.18 |
